

## Eliquis® (apixaban) - New indication, new formulation

- On April 17, 2025, the FDA approved Bristol Myers Squibb's <u>Eliquis (apixaban)</u>, for the treatment
  of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric
  patients from birth and older after at least 5 days of initial anticoagulant treatment.
- Eliquis is also approved:
  - To reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation
  - For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery
  - For the treatment of adults with DVT
  - For the treatment of adults with PE
  - To reduce the risk of recurrent DVT and PE in adult patients following initial therapy.
- In addition to the new indication, Eliquis was also approved as a 0.5 mg tablet for oral suspension and a 0.15 mg capsule for oral suspension.
- The approval of Eliquis for the new indication was based on Study CV185325, a randomized, active-controlled, open-label study in 229 pediatric patients from birth to less than 18 years with confirmed VTE. Patients were randomized to receive either an age-appropriate formulation and body weight-adjusted dose of Eliquis or standard of care.
  - The percentage of patients with symptomatic and asymptomatic recurrent VTE and VTE related mortality was 2.6% (95% CI: 0.7, 6.5) with Eliquis vs. 2.7% (95% CI: 0.3, 9.4) with standard of care.
- Eliquis carries a boxed warning for premature discontinuation increases the risk of thrombotic events and spinal/epidural hematoma.
- The most common adverse reactions (≥ 10%) with Eliquis use in pediatric patients were headache, vomiting, and excessive menstrual bleeding.
- Refer to the Eliquis drug label for completing dosing and administration recommendations in both adult and pediatric patients.
- Bristol Myers Squibb's launch plans for the tablet for oral suspension and capsule for oral suspension are pending.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.